Acute Myeloid Leukemia Harboring the t(16;21)(p11;q22) Translocation Treated With Venetoclax Plus Azacitidine After Cord Blood Transplantation

A 62-year-old female was diagnosed with acute myeloid leukemia (AML) t(16;21)(p11;q22). She achieved complete hematological remission after induction therapy and underwent umbilical cord blood stem cell transplantation (CBT). At 150 days the CBT, a bone marrow examination revealed relapse. We treated patient venetoclax plus azacitidine as salvage therapy. After five cycles of therapy, died due to disease progression. The prognosis AML t(16;21)(p11;q22) is very poor owing high rate early relapse even hematopoietic transplantation. Therefore, novel therapeutic approach required improve outcomes.